Study of CYP3A5 gene expression and polymorphisms in hypercholesterolemic individuals treated with atorvastatin / Estudo da expressão gênica e de polimorfismos da CYP3A5 em pacientes com hipercolesterolemia tratados com atorvastatina
AUTOR(ES)
Maria Alice Vieira Willrich
DATA DE PUBLICAÇÃO
2006
RESUMO
The cytochrome P450 isoenzyme 3A5 (CYP3A5) has an important role on biotransformation of endogenous compounds and xenobiotics. Single nucleotide polymorphisms (SNPs) of the CYP3A5 gene have been associated with variations on gene expression and enzyme activity that can modify the metabolism of several drugs. In order to evaluate the influence of CYP3A5 SNPs on RNAm expression and response to atorvastatin, 99 mormolipidemic (NL) and 139 hypercholesterolemic (HC) individuals have been enrolled in this study. HC patients were treated with atorvastatin (10 mg/day/four weeks). Blood samples were collected before and after treatment for serum lipids analyses, genomic DNA and total RNA extraction. CYP3A5*3C, and CYP3A5*6 SNPs were analyzed by PCR-RFLP. CYP3A5*1D was analyzed by direct sequencing. CYP3A5 RNAm expression in peripheral blood mononuclear cells (PBMC) was evaluated by Real Time PCR. In HC group, the frequencies of CYP3A5*3C and CYP3A5*1D alleles were higher in white individuals (*3C: 84.9% and *1D 84.8%) that in blacks (*3C: 47.8% and *1D: 55.2%, p<0.01). CYP3A5*3C and *1D alleles were in linkage desequilibrium. CYP3A5*6 allelle frequency was higher in blacks (6.8%) that in white individuals (0.6%, p=0.002). There was no association between CYP3A5 SNPs and baseline lipid profile in NL and HC groups. White HC carriers of CYP3A5*3A/*3A haplotype (*3C and *1D combined alleles) have lower total cholesterol and LDL-c response to atorvastatin than non-CYP3A5*3A/*3A carriers (p<0.05). CYP3A5 RNAm expression on PBMC increased in response to atorvastatin (p<0.05) only in CYP3A5*3A/*3A haplotype carriers. These results are suggestive that CYP3A5*3C and CYP3A5*1D SNPs are associated with CYP3A5 gene expression and cholesterol-lowering response to atorvastatin.
ASSUNTO(S)
farmacogenética gene expression cyp3a5 atorvastatina atorvastatin pharmacogenetics hypercholesterolemia cyp3a5 expressão gênica hipercolesterolemia
Documentos Relacionados
- CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin
- Efeitos de hipolipemiantes sobre a expressão de CYP3A4 e CYP3A5 in vitro e in vivo
- ABCA1 gene expression and polymorphisms on patients under hypolipemic therapy
- Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
- Gene expression and cell behavior study in cells from individuals with syndromic craniosynostosis